Literature DB >> 26435673

Preventing hospitalizations for respiratory syncytial virus infection.

Joan L Robinson, Nicole Le Saux.   

Abstract

Respiratory syncytial virus infection is the leading cause of lower respiratory tract infections in young children. Palivizumab has minimal impact on RSV hospitilization rates as it is only practical to offer it to the highest risk groups. The present statement reviews the published literature and provides updated recommendations regarding palivizumab use in children in Canada.

Entities:  

Keywords:  At-risk infants; Chronic lung disease; Congenital heart disease; Palivizumab; Prematurity; Prophylaxis; RSV

Year:  2015        PMID： 26435673      PMCID： PMC4578474          DOI： 10.1093/pch/20.6.321

Source DB:  PubMed          Journal:  Paediatr Child Health        ISSN： 1205-7088            Impact factor:   2.253


  58 in total

1.  Results of clinical surveillance during the Japanese first palivizumab season in 2002-2003.

Authors:  Satoshi Kusuda; Takenobu Koizumi; Takeo Sakai; Masanori Fujimura; Hiroshi Nishida; Hajime Togari
Journal:  Pediatr Int       Date:  2006-08       Impact factor: 1.524

2.  Risk factors and viruses associated with hospitalization due to lower respiratory tract infections in Canadian Inuit children : a case-control study.

Authors:  Anna Banerji; David Greenberg; Laura Forsberg White; W Alexander Macdonald; Audrey Saxton; Eva Thomas; Douglas Sage; Muhammad Mamdani; Krista L Lanctôt; James B Mahony; Mia Dingle; Ann Roberts
Journal:  Pediatr Infect Dis J       Date:  2009-08       Impact factor: 2.129

3.  Respiratory syncytial virus infections in pediatric transplant recipients: A Canadian Paediatric Surveillance Program study.

Authors:  Joan L Robinson; Danielle Grenier; Ian MacLusky; Upton D Allen
Journal:  Pediatr Transplant       Date:  2015-07-07

4.  Palivizumab and respiratory syncytial virus immune globulin intravenous for the prophylaxis of respiratory syncytial virus infection in high risk infants.

Authors: 
Journal:  Paediatr Child Health       Date:  1999-10       Impact factor: 2.253

Review 5.  The cost effectiveness of palivizumab: a systematic review of the evidence.

Authors:  Kelly A Smart; Krista L Lanctôt; Bosco A Paes
Journal:  J Med Econ       Date:  2010       Impact factor: 2.448

6.  Safety, tolerance and pharmacokinetics of a humanized monoclonal antibody to respiratory syncytial virus in premature infants and infants with bronchopulmonary dysplasia. MEDI-493 Study Group.

Authors:  K N Subramanian; L E Weisman; T Rhodes; R Ariagno; P J Sánchez; J Steichen; L B Givner; T L Jennings; F H Top; D Carlin; E Connor
Journal:  Pediatr Infect Dis J       Date:  1998-02       Impact factor: 2.129

7.  Direct cost analyses of palivizumab treatment in a cohort of at-risk children: evidence from the North Carolina Medicaid Program.

Authors:  Steven Wegner; Julie Jacobson Vann; Gordon Liu; Patricia Byrns; Clement Cypra; William Campbell; Alan Stiles
Journal:  Pediatrics       Date:  2004-12       Impact factor: 7.124

8.  Down syndrome: a novel risk factor for respiratory syncytial virus bronchiolitis--a prospective birth-cohort study.

Authors:  Beatrijs L P Bloemers; A Marceline van Furth; Michel E Weijerman; Reinoud J B J Gemke; Chantal J M Broers; Kimberly van den Ende; Jan L L Kimpen; Jan L M Strengers; Louis J Bont
Journal:  Pediatrics       Date:  2007-10       Impact factor: 7.124

9.  Prophylaxis against respiratory syncytial virus in young children with cystic fibrosis.

Authors:  Karin Giebels; Jacques-Edouard Marcotte; John Podoba; Céline Rousseau; Marie-Hélène Denis; Véronique Fauvel; Sophie Laberge
Journal:  Pediatr Pulmonol       Date:  2008-02

Review 10.  Effectiveness of Palivizumab in Preventing RSV Hospitalization in High Risk Children: A Real-World Perspective.

Authors:  Nusrat Homaira; William Rawlinson; Thomas L Snelling; Adam Jaffe
Journal:  Int J Pediatr       Date:  2014-12-04
View more
  25 in total

1.  Reducing the burden of lower respiratory tract infections in infants in the Canadian Arctic.

Authors:  Ian Mitchell; Delshani Peiris
Journal:  CMAJ       Date:  2017-03-27       Impact factor: 8.262

2.  Respiratory syncytial virus prophylaxis in infants with congenital airway anomalies compared to standard indications and complex medical disorders.

Authors:  Bosco Paes; Doyoung Kim; Mahwesh Saleem; Sophie Wong; Ian Mitchell; Krista L Lanctot
Journal:  Eur J Pediatr       Date:  2019-01-04       Impact factor: 3.183

Review 3.  Follow-up care of the extremely preterm infant after discharge from the neonatal intensive care unit.

Authors:  Leonora Hendson; Paige T Church; Rudaina Banihani
Journal:  Paediatr Child Health       Date:  2022-10-03       Impact factor: 2.600

Review 4.  Le suivi de l'extrême prématuré après le congé des soins intensifs néonatals.

Authors:  Leonora Hendson; Paige T Church; Rudaina Banihani
Journal:  Paediatr Child Health       Date:  2022-10-03       Impact factor: 2.600

5.  Respiratory syncytial virus prophylaxis in cystic fibrosis: the Canadian registry of palivizumab data (2005-2016).

Authors:  Ian Mitchell; S K Wong; B Paes; M Ruff; C Bjornson; A Li; K L Lanctôt
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2018-05-04       Impact factor: 3.267

6.  Respiratory Syncytial Virus Infection Rates with Limited Use of Palivizumab for Infants Born at 29 to 31+6/7 Weeks Gestational Age.

Authors:  Brandi Newby; Todd Sorokan
Journal:  Can J Hosp Pharm       Date:  2017-02-28

7.  Evaluating the Individual Healthcare Costs and Burden of Disease Associated with RSV Across Age Groups.

Authors:  Ellen Rafferty; Mike Paulden; Sarah A Buchan; Joan L Robinson; Julie A Bettinger; Manoj Kumar; Lawrence W Svenson; Shannon E MacDonald
Journal:  Pharmacoeconomics       Date:  2022-05-13       Impact factor: 4.558

Review 8.  Defining the Risk and Associated Morbidity and Mortality of Severe Respiratory Syncytial Virus Infection Among Infants with Chronic Lung Disease.

Authors:  Bosco Paes; Brigitte Fauroux; Josep Figueras-Aloy; Louis Bont; Paul A Checchia; Eric A F Simões; Paolo Manzoni; Xavier Carbonell-Estrany
Journal:  Infect Dis Ther       Date:  2016-11-18

Review 9.  Defining the Risk and Associated Morbidity and Mortality of Severe Respiratory Syncytial Virus Infection Among Infants with Congenital Heart Disease.

Authors:  Paul A Checchia; Bosco Paes; Louis Bont; Paolo Manzoni; Eric A F Simões; Brigitte Fauroux; Josep Figueras-Aloy; Xavier Carbonell-Estrany
Journal:  Infect Dis Ther       Date:  2017-01-09

10.  Burden of Severe Respiratory Syncytial Virus Disease Among 33-35 Weeks' Gestational Age Infants Born During Multiple Respiratory Syncytial Virus Seasons.

Authors:  Evan J Anderson; Xavier Carbonell-Estrany; Maarten Blanken; Marcello Lanari; Margaret Sheridan-Pereira; Barry Rodgers-Gray; John Fullarton; Elisabeth Rouffiac; Pamela Vo; Gerard Notario; Fiona Campbell; Bosco Paes
Journal:  Pediatr Infect Dis J       Date:  2017-02       Impact factor: 2.129
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.